This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wallace, D J Articles by Tumlin, J A Search for Related Content PubMed PubMed Citation Articles by Wallace, D J Articles by Tumlin, J A Social Bookmarking                   What's this?

LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus

Department of Medicine, Division of Rheumatology, Cedars-Sinai/UCLA School of Medicine, Los Angeles, USA, dwallace{at}ucla.edu

J A Tumlin

Emory University School of Medicine, Atlanta, Georgia, USA

LJP 394 (abetimus, Riquent, La Jolla Pharmaceuticals)is four oligonucleotideB cell toleragen which acts as an ‘anti-anti DNA’. Given as a weekly infusion, Phase 1, 2, and 3 studies with this biologic on close to 1,000 patients have demonstrated no toxicity of any note. In patients with lupus nephritis and an elevated anti-DNA (Farr assay) who have a high affinity to LJP 394, the drug significantly decreases anti-DNA, improves quality of life, and trends towards reducing renal flares. LJP 394 is a promising inductionand/or maintenancetherapy for lupus patients with elevated anti-DNA and active disease.

Key Words: anti DNA • biologic • lupus • treatment

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. W. Edwards and G. Cambridge Prospects for B-cell-targeted therapy in autoimmune disease Rheumatology, February 1, 2005; 44(2): 151 - 156. [Full Text] [PDF]